In our EuroBiotech roundup this week, Motif Bio sets IPO terms, MSP plans a £60 million laboratory development, Prokarium bags cash for plague R&D and more.

Regulus Therapeutics saw its shares nosedive last month when the FDA put a clinical trial hold on its leading hep C candidate RG-101--but the company said this…

Genmab and J&J bag a breakthrough designation, Merck dumps ALK, uniQure yo-yos on gene therapy data and more.

Shares in uniQure briefly hit a new low following a negative knee-jerk reaction to fresh data on its hemophilia B gene therapy.

Specialty pharma InnoPharma was acquired by Pfizer a few years ago for up to $360 million. Now, the team behind that effort is at it again with another…

GlaxoSmithKline will pay up to £175 million ($230 million) to gain global, exclusive rights to a Phase I monoclonal antibody to treat severe asthma from…

Unlikely IPO candidate Kadmon made it out in a tough IPO market amid swirling criticisms of its rather infamous current and former management, namely the…

Building on the original 2013 R&D deal between Japan’s Astellas and Cytokinetics, the two have now expanded their initial collab, which will see Astellas…